TCGA-4P-AA8J-01A-11R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- MYOGENESIS+0.390
- PANCREAS_BETA_CELLS+0.340
- COAGULATION+0.310
- ANGIOGENESIS+0.240
- APICAL_JUNCTION+0.210
- DNA_REPAIR+0.160
- OXIDATIVE_PHOSPHORYLATION+0.160
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.120
- KRAS_SIGNALING_DN+0.090
Top 10 suppressed
- G2M_CHECKPOINT-0.520
- E2F_TARGETS-0.510
- MITOTIC_SPINDLE-0.430
- PROTEIN_SECRETION-0.410
- MTORC1_SIGNALING-0.360
- ANDROGEN_RESPONSE-0.340
- HEME_METABOLISM-0.330
- CHOLESTEROL_HOMEOSTASIS-0.310
- MYC_TARGETS_V1-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A66N-01A-12R-A31O-07 | — | B | 0.814 |
| 2 | TCGA-XF-A9SP-01A-11R-A39I-07 | — | — | 0.813 |
| 3 | TCGA-AO-A126-01A-11R-A10J-07 | — | A | 0.811 |
| 4 | SRR15069599 | — | — | 0.809 |
| 5 | TCGA-GM-A5PX-01A-12R-A28M-07 | — | A | 0.808 |
| 6 | TCGA-5L-AAT0-01A-12R-A41B-07 | — | A | 0.798 |
| 7 | TCGA-AC-A3QP-01A-11R-A22U-07 | — | B | 0.794 |
| 8 | SRR2932812 | — | — | 0.791 |
| 9 | TCGA-AC-A2QJ-01A-12R-A19W-07 | — | A | 0.791 |
| 10 | TCGA-GM-A2D9-01A-11R-A18M-07 | — | B | 0.789 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.340 | Cobimetinib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.050 | Idelalisib | — uncovered |
| COMPLEMENT | 0.050 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.030 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.020 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |